In vivo Study of a Newly Synthesized Chromen-4-one Derivative as an Antitumor Agent against HCC
ConclusionThe ability of the new Ch derivative to control the primary initiators of HCC such as TNF- α offers this derivative an anti-tumor activity and encourages further researches to follow and monitor its effect on the molecular level.Graphical Abstract
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Antidoxidants | Cancer | Cancer & Oncology | Chemistry | Gastroenterology | Genetics | Molecular Biology | Nutrition | Study